EXEL Stock

Exelixis, Inc (EXEL) was a top stock pick based on predictive algorithm recommended to I Know First subscribers on May 1st for the 7 day time horizon. EXEL had a signal of 61.74 and a predictability of 0.27. In accordance with the algorithm, the company reported short-term capital gains of 33.46%.

EXEL was part of the stock forecast that can be found in the “Industry” Package.

The full BioTech Stocks forecast includes a daily prediction for a total of 20 stocks with bullish and bearish signals:

• top ten biotech stocks picks to long
• top ten biotech stocks picks to short

Get the “Industry Package – BioTech Stocks”

Exelixis, Inc. is a biopharmaceutical company based in San Francisco. Exelexis is committed to develop and commercialize small molecule therapies with the potential to improve the cancer treatments.

Over the past decade, Exelexis has established a broad development platform, laying the foundation for continued efforts to develop new therapies for cancer. The history of lead compounds like cabozantinib and cobimetinib were discovered in Exelexis own laboratories and advanced by Exelexis into clinical development.

EXEL reported its first quarter results on Thursday, 30th of April. Net income is $35.2 million, which translates into a loss of 18 cents per share, beating analysts’ net loss expectations of 23 cents per share. Also, the revenue beats analysts expectations: The revenue for the first quarter is $9.4 million while the analysts expected $8.3 million.

Before making any trading decisions, consult the latest forecast as the algorithm constantly updates predictions daily. While the algorithm can be used for intra-day trading the predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.

Missed the latest trend? Looking for the next best market opportunity? Find out today’s stock forecast based on our advanced self-learning algorithm